Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.71 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.71 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.71 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.71 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.71 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.71 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.65 |
| ▸ | HTR3B | O95264 | 2/20 | 0.65 |
| ▸ | HTR3A | P46098 | 2/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | DRD1 | P21728 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23521033 | 0.78 | GRIN2B (0.74) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15903395 | 0.77 | TAAR1 (0.73) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| Iobenguane I 131 SCHEMBL29431814 | 0.77 | GRIN2B (0.71) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL538276 | 0.77 | HTR3E (0.96) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| M-Fluorobenzylguanidine SCHEMBL4335227 | 0.77 | TAAR1 (0.75) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| Iobenguane SCHEMBL140592 | 0.77 | CYP1A2 (1.00) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| Iobenguane I 123 SCHEMBL29381016 | 0.77 | HTR1A (1.00) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| Iobenguane SCHEMBL16040804 | 0.76 | CYP1A2 (0.96) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL45769 | 0.74 | GRIN2B (0.68) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8661054 | 0.73 | GRIN2B (0.65) | GRIN2BGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4148018-B1 | SIMPLE ASTATINE CONCENTRATION METHOD | INST OF SCIENCE TOKYO (JP) | 2025-09-24 | — | — | EP | disclosed |
| US-20250152757-A1 | Radiopharmaceutical Compositions of Radioactive Halogenated Benzylguandine | JUBILANT DRAXIMAGE INC (CA) | 2025-05-15 | — | — | US | disclosed |
| US-20250032649-A1 | Radiopharmaceutical Compositions of Radioactive Halogenated Benzylguandine | JUBILANT DRAXIMAGE INC (CA) | 2025-01-30 | — | — | US | disclosed |
| CN-113301920-B | Complexes comprising a ligand, a spacer, a peptide linker and a biomolecule | 安斯泰来制药株式会社 | 2025-01-14 | — | — | CN | disclosed |
| US-20230373881-A1 | SIMPLE ASTATINE CONCENTRATION METHOD | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2023-11-23 | — | — | US | disclosed |
| EP-4148018-A1 | SIMPLE ASTATINE CONCENTRATION METHOD | Tokyo Institute of Technology (JP) | 2023-03-15 | — | — | EP | disclosed |
| US-20220354974-A1 | REAGENTS AND METHODS FOR LABELING MOLECULES WITH ASTATINE ISOTOPES IN HIGHER OXIDATION STATES | UNIVERSITY OF WASHINGTON (US) | 2022-11-10 | — | — | US | disclosed |
| US-20220296734-A1 | RADIOPHARMACEUTICAL COMPOSITIONS OF RADIOACTIVE HALOGENATED BENZYLGUANIDINE | JUBILANT DRAXIMAGE INC. (CA) | 2022-09-22 | — | — | US | disclosed |
| US-11351276-B2 | Radiopharmaceutical compositions of radioactive halogenated benzylguanidine | JUBILANT DRAXIMAGE INC. (CA) | 2022-06-07 | — | — | US | disclosed |
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
| US-20220096653-A1 | CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | ASTELLAS PHARMA INC. (JP) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | GRIN2B 2340/4885GRIN2D 1610/4885GRIN3B 632/4885 |
| US-20220354974-A1 | REAGENTS AND METHODS FOR LABELING MOLECULES WITH ASTATINE ISOTOPES IN HIGHER OXIDATION STATES | AADAT, CKMT1A; CKMT1B, MB | GRIN2B 1418/4885GRIN2D 1248/4885GRIN3B 454/4885 |
| US-20220296734-A1 | RADIOPHARMACEUTICAL COMPOSITIONS OF RADIOACTIVE HALOGENATED BENZYLGUANIDINE | VHL, GCG, RB1 | GRIN2B 4076/4885GRIN2D 4412/4885GRIN3B 3642/4885 |
| US-11351276-B2 | Radiopharmaceutical compositions of radioactive halogenated benzylguanidine | VHL, GCG, RB1 | GRIN2B 4076/4885GRIN2D 4412/4885GRIN3B 3642/4885 |
| US-20230373881-A1 | SIMPLE ASTATINE CONCENTRATION METHOD | VIM, POLH, ALPL | GRIN2B 1751/4885GRIN2D 2417/4885GRIN3B 1216/4885 |
| US-20220096653-A1 | CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | SIGLEC7, TNFSF11, FCGR2A | GRIN2B 3540/4885GRIN2D 3893/4885GRIN3B 2522/4885 |
| US-20250152757-A1 | Radiopharmaceutical Compositions of Radioactive Halogenated Benzylguandine | GCG, VHL, SHBG | GRIN2B 4220/4885GRIN2D 4393/4885GRIN3B 3811/4885 |
| US-20250032649-A1 | Radiopharmaceutical Compositions of Radioactive Halogenated Benzylguandine | GCG, VHL, SHBG | GRIN2B 4220/4885GRIN2D 4393/4885GRIN3B 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.